ABL-class fusion positive acute lymphoblastic leukemia: can targeting ABL cure ALL?

Haematologica. 2020 Jul;105(7):1754-1757. doi: 10.3324/haematol.2020.252916.

Authors

Thai Hoa Tran¹, Stephen P Hunger²

Affiliations

¹ Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
² Department of Pediatrics, The Center for Childhood Cancer Research, Children's Hospital of Philadelphia, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

B-Lymphocytes
Child
Fusion Proteins, bcr-abl / genetics
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Prognosis
Recurrence

Substances

Fusion Proteins, bcr-abl

Grants and funding